doi: 10.1161/hc2601.092124
(Circulation. 2001;104:4.)
© 2001 American Heart Association, Inc.
Editorials |
Inflammatory Cardiomyopathy (Myocarditis)
Which Patients Should Be Treated With Anti-Inflammatory Therapy?
From the Section of Cardiology, Rush-Presbyterian-St Luke’s Medical Center, Chicago, Ill.
Correspondence to Joseph E. Parrillo, MD, the Section of Cardiology, Rush-Presbyterian-St Luke’s Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612. E-mail jparrill@rush.edu
Key Words: Editorials • inflammation • cardiomyopathy • myocarditis • immunohistochemistry • heart failure
In patients presenting with congestive heart failure in the United States, approximately one-quarter have idiopathic dilated cardiomyopathy (IDC). IDC is thought to result from a number of mechanisms that injure the myocardium and lead to a common pathway of cardiac dilatation and heart failure. Known mechanisms of myocardial injury include alcohol, toxins, infections, cytotoxic chemotherapy, and metabolic abnormalities.1 Recent studies have highlighted important genetic links, suggesting that familial transmission is important in a subgroup of IDC patients. However, in most IDC patients, a cause cannot be determined.
Substantial animal experimental data has demonstrated a strong pathogenetic link between infectious agents (usually viruses) and subsequent immune-mediated damage to the myocardium resulting in IDC.2 3 Human studies have demonstrated a high prevalence of viral genome in the hearts of patients with IDC. Enteroviruses, adenovirus, influenza, HIV, and hepatitis C have been implicated in the pathogenesis of dilated cardiomyopathy and myocarditis. Much of the data suggests cell-mediated immune damage, although cytokines and antibodies have also been hypothesized to play a role.3 4
Patients with heart failure due to IDC should be treated
with conventional heart failure regimens, including diuretics,
angiotensin-converting enzyme (ACE) inhibitors,
digitalis, ß-blockers, vasodilators, aldosterone
antagonists, and other effective medications and
technology. However, the specific question for patients with an
inflammatory cardiomyopathy is whether a regimen
designed to reduce or eliminate inflammation would provide added
clinical benefit compared with conventional heart failure therapy. This
has been a difficult question to answer for several reasons. First, the
clinical presentation of inflammatory
cardiomyopathy is very
This article has been cited by other articles:
 |
|
 |
|
  L. Brunetti and E. R. H. DeSantis Treatment of viral myocarditis caused by coxsackievirus B Am. J. Health Syst. Pharm., January 15, 2008; 65(2): 132 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology Eur. Heart J., December 2, 2007; 28(24): 3076 - 3093. [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1914 - 1931. [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Circulation, November 6, 2007; 116(19): 2216 - 2233. [Full Text] [PDF]
|
|
|
|
|
|
J. W. Magnani and G. W. Dec Myocarditis: Current Trends in Diagnosis and Treatment Circulation, February 14, 2006; 113(6): 876 - 890. [Full Text] [PDF]
|
|
|
|
 |
|
 C P P Hia, W C L Yip, B C Tai, and S C Quek Immunosuppressive therapy in acute myocarditis: an 18 year systematic review Arch. Dis. Child., June 1, 2004; 89(6): 580 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Noutsias, M. Pauschinger, H.-P. Schultheiss, and U. Kuhl Cytotoxic perforin+ and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy Eur J Heart Fail, August 1, 2003; 5(4): 469 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Noutsias, M. Pauschinger, H.-P. Schultheiss, and U. Kuhl Advances in the immunohistological diagnosis of inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I54 - I62. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Page, D. Assouline, O. Brun, D. Coeffic, D. Fric, P. Winckel, A. D. Seidman, M. K. Pierri, and C. Hudis Cardiac Dysfunction in Clinical Trials of Trastuzumab J. Clin. Oncol., October 1, 2002; 20(19): 4119 - 4120. [Full Text] [PDF]
|
|